$170 Million is the total value of Bain Capital Life Sciences Investors, LLC's 4 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DRNA | DICERNA PHARMACEUTICALS INC | $85,373,000 | +5.9% | 8,930,237 | 0.0% | 50.34% | -4.9% | |
| IFRX | INFLARX NV | $54,116,000 | +37.7% | 1,876,413 | 0.0% | 31.91% | +23.7% | |
| MRNS | MARINUS PHARMACEUTICALS INC | $15,194,000 | -53.2% | 3,977,453 | 0.0% | 8.96% | -57.9% | |
| SLDB | New | SOLID BIOSCIENCES INC | $14,921,000 | – | 1,989,444 | +100.0% | 8.80% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, L.P. #2
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| SAVARA INC | 16 | Q3 2023 | 6.0% |
| X4 PHARMACEUTICALS INC | 16 | Q3 2023 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 15 | Q3 2023 | 20.1% |
| MERSANA THERAPEUTICS, INC. | 14 | Q3 2023 | 8.4% |
| CRINETICS PHARMACEUTICALS, INC. | 14 | Q3 2023 | 5.4% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-05-30 |
| 4 | 2023-05-30 |
| 13F-HR | 2023-05-15 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.